Plexus Insider Sold Shares Worth $659,043, According to a Recent SEC Filing-March 2024-www.financetom.com

Plexus Insider Sold Shares Worth $659,043, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Plexus Insider Sold Shares Worth $659,043, According to a Recent SEC Filing

May 3, 2024 1:54 PM

04:38 PM EDT, 05/03/2024 (MT Newswires) -- Patrick John Jermain, Executive Vice President & CFO, on May 01, 2024, sold 6,500 shares in Plexus (PLXS) for $659,043. Following the Form 4 filing with the SEC, Jermain has control over a total of 44,748 shares of the company, with 41,182 shares held directly and 3,566 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/785786/000162828024020325/xslF345X03/wk-form4_1714768276.xml

Previous page： Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint Next page： CytomX Names Rachael Lester as Chief Business Officer

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint

Oct 20, 2025

05:18 PM EDT, 10/20/2025 (MT Newswires) -- Neuphoria Therapeutics ( NEUP ) said Monday that a phase 3 trial of BNC210 for the acute treatment of social anxiety disorder did not meet its primary endpoint. Additionally, analyses of secondary endpoints did not show statistically significant differences, the company said. Neuphoria said that following the results of the trial, it will...

CytomX Names Rachael Lester as Chief Business Officer

Oct 20, 2025

05:13 PM EDT, 10/20/2025 (MT Newswires) -- CytomX Therapeutics ( CTMX ) said late Monday it has appointed Rachael Lester as chief business officer. Lester most recently worked at Replicate Bioscience in the same role, CytomX said. Shares of CytomX rose 1.3% in recent after-market hours activity. ...

Verrica Pharmaceuticals Cleared to File for EU Approval of Molluscum Treatment

Oct 20, 2025

05:11 PM EDT, 10/20/2025 (MT Newswires) -- Verrica Pharmaceuticals ( VRCA ) said Monday it received positive feedback from the European Medicines Agency supporting a marketing application for YCANTH, its treatment for molluscum contagiosum, in the European Union. The agency's Committee for Medicinal Products for Human Use said Verrica's prior Phase 3 studies in the US and Japan are adequate...

Wintrust Financial Q3 Earnings, Revenue Rise

Oct 20, 2025

05:11 PM EDT, 10/20/2025 (MT Newswires) -- Wintrust Financial ( WTFC ) reported Q3 earnings late Monday of $2.78 per diluted share, up from $2.47 a year earlier. Analysts polled by FactSet expected $2.63 per share. Revenue, expressed as the sum of net interest income and noninterest income, for the quarter ended Sept. 30 was $697.8 million, up from $615.7...